Crinetics Pharmaceuticals, Inc.
10222 Barnes Canyon Road, Bldg. #2
San Diego, CA 92121
August 27, 2019
VIA EDGAR
Ms. Mary Beth Breslin
Branch Chief
Office of Healthcare and Insurance
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Crinetics Pharmaceuticals, Inc. |
| Registration Statement on Form S-3 |
| File No. 333-233246 |
Dear Ms. Breslin:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Crinetics Pharmaceuticals, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on Thursday, August 29, 2019, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| CRINETICS PHARMACEUTICALS, INC. | ||
| By: | /s/ Marc J.S. Wilson | |
| Marc J.S. Wilson | ||
| Chief Financial Officer | ||
| cc: | R. Scott Struthers, Ph.D., Crinetics Pharmaceuticals, Inc. |
Cheston J. Larson, Esq., Latham & Watkins LLP
Matthew T. Bush, Esq., Latham & Watkins LLP
Kevin C. Reyes, Esq., Latham & Watkins LLP